Log in

NASDAQ:NKNantkwest Stock Price, Forecast & News

$10.52
+0.01 (+0.10 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.22
Now: $10.52
$10.90
50-Day Range
$8.15
MA: $12.24
$15.36
52-Week Range
$1.04
Now: $10.52
$15.70
Volume1.42 million shs
Average Volume1.35 million shs
Market Capitalization$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.02
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Read More
Nantkwest logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.02 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone858-633-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40,000.00
Price / Sales25,908.13
Book Value$1.23 per share

Profitability

Net Income$-65,790,000.00
Net Margins-112,350.85%

Miscellaneous

Employees161
Market Cap$1.04 billion
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable
$10.52
+0.01 (+0.10 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nantkwest (NASDAQ:NK) Frequently Asked Questions

How has Nantkwest's stock been impacted by COVID-19 (Coronavirus)?

Nantkwest's stock was trading at $3.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NK shares have increased by 198.9% and is now trading at $10.52.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Nantkwest?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nantkwest
.

When is Nantkwest's next earnings date?

Nantkwest is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Nantkwest
.

How were Nantkwest's earnings last quarter?

Nantkwest Inc (NASDAQ:NK) issued its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. Nantkwest had a negative net margin of 112,350.85% and a negative return on equity of 51.94%.
View Nantkwest's earnings history
.

What price target have analysts set for NK?

1 Wall Street analysts have issued 1-year price objectives for Nantkwest's shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate Nantkwest's share price to reach $18.00 in the next year. This suggests a possible upside of 71.1% from the stock's current price.
View analysts' price targets for Nantkwest
.

Has Nantkwest been receiving favorable news coverage?

Media stories about NK stock have been trending very positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nantkwest earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Nantkwest
.

Are investors shorting Nantkwest?

Nantkwest saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 4,890,000 shares, a drop of 9.8% from the July 15th total of 5,420,000 shares. Based on an average daily volume of 2,460,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 14.0% of the shares of the stock are short sold.
View Nantkwest's Current Options Chain
.

Who are some of Nantkwest's key competitors?

What other stocks do shareholders of Nantkwest own?

Who are Nantkwest's key executives?

Nantkwest's management team includes the following people:
  • Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 66)
  • Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 54)
  • Mr. Richard J. Tajak, Consultant (Age 66)
  • Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 46)
  • Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 62)

When did Nantkwest IPO?

(NK) raised $150 million in an initial public offering on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

What is Nantkwest's stock symbol?

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Who are Nantkwest's major shareholders?

Nantkwest's stock is owned by a variety of institutional and retail investors. Top institutional investors include Meridian Investment Counsel Inc. (0.10%), Creative Planning (0.06%), New York State Common Retirement Fund (0.03%), Principal Financial Group Inc. (0.02%), UBS Group AG (0.02%) and SG Americas Securities LLC (0.02%). Company insiders that own Nantkwest stock include Barry J Simon, John C Thomas, Patrick Soon-Shiong and Steve Gorlin.
View institutional ownership trends for Nantkwest
.

Which institutional investors are buying Nantkwest stock?

NK stock was acquired by a variety of institutional investors in the last quarter, including Meridian Investment Counsel Inc., New York State Common Retirement Fund, Principal Financial Group Inc., SG Americas Securities LLC, Creative Planning, State Board of Administration of Florida Retirement System, UBS Group AG, and Strs Ohio.
View insider buying and selling activity for Nantkwest
.

How do I buy shares of Nantkwest?

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nantkwest's stock price today?

One share of NK stock can currently be purchased for approximately $10.52.

How big of a company is Nantkwest?

Nantkwest has a market capitalization of $1.04 billion and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Nantkwest employs 161 workers across the globe.

What is Nantkwest's official website?

The official website for Nantkwest is www.nantkwest.com.

How can I contact Nantkwest?

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.